Avid Bioservices to Participate at BIO International Convention 2018
29 Mai 2018 - 2:05PM
-- Corporate Booth to Include Virtual Tour of
Myford Late-Stage Clinical and Commercial Biomanufacturing Facility
Highlighting Immediately Available 2,000-Liter Scale Bioreactor
Capacity --
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated
biologics contract development and manufacturing organization
(CDMO) working to improve patient lives by providing high quality
development and manufacturing services to biotechnology and
pharmaceutical companies, today announced that the company will
participate at the upcoming 2018 BIO International
Convention. The company’s activities will include hosting of
a corporate booth (#1073) in the conference’s exhibit hall,
delivering a presentation on single-use manufacturing of
biopharmaceuticals, participating in a roundtable discussion on the
topic of capacity strategies for the utilization of single-use
systems vs. traditional stainless steel technology, and taking part
in the conference’s one-on-one partnering meetings. The
company will also hold a reception at its booth on the evening of
Tuesday, June 5th as part of the exhibit hall activities taking
place on opening day. BIO 2018 is being held June 4-7, 2018
in Boston, MA.
Details of Avid’s activities at BIO 2018 are as
follows:
- Avid will host corporate booth #1073 showcasing the company’s
comprehensive range of process development, high quality cGMP
clinical and commercial manufacturing services. Company
representatives will provide a virtual tour of Avid’s 42,000 square
foot state-of-the-art commercial biomanufacturing suite (Myford
facility), which is in the unique position of being a validated
facility with immediately available 2,000-liter scale bioreactor
capacity. The company will also discuss the ongoing expansion
of its process development capabilities and laboratories.The Myford
facility, located in Tustin, California, incorporates a variety of
cutting-edge, single-use equipment with the goal of ultimately
accommodating a fully disposable biomanufacturing process. A
wide range of innovative features are incorporated into the
facility including monolithic modular clean rooms, dedicated
support utilities for each key processing area, and the industry’s
most advanced single-use production systems and flexible
solutions. Uni-directional process flows separate personnel
and materials and provide assurance that the design meets the most
stringent regulatory requirements for commercial biologics drug
substance manufacturing.Additionally, Avid will dedicate a portion
of its booth to celebrating the company’s 25 years of experience in
biopharmaceutical development and manufacturing, which dates back
to 1993. This anniversary coincides with the 25-year
anniversary of the Biotechnology Innovation Organization (BIO),
which is also being celebrated this year.
- Joining the Avid team at BIO 2018 will be Sandra C. Carbonneau,
the company’s newly appointed director of business development for
the East Coast. Mrs. Carbonneau has more than 26 years of
relevant industry experience, including a 22-year tenure with
Lonza, a global integrated solutions provider to the pharmaceutical
and biotechnology industries. During her time with Lonza, she
held positions of increasing responsibility spanning areas of
manufacturing, quality assurance, compliance and contract
management, culminating in her overseeing the company’s global
commercial development for its mammalian business unit. Mrs.
Carbonneau most recently served as director of business development
in the New England region at Integrated Project Services (IPS), a
leading consulting firm for technically complex facilities
worldwide. At Avid, she will play a key role in the company’s new
customer acquisition efforts on the east coast of the US, while
supporting all its existing clients in the eastern half of the
country.
- Roger Lias, Ph.D., Avid’s president and chief executive
officer, will participate in a roundtable discussion titled,
“Capacity Strategies – The Strategy Behind the Large Scale SUS vs.
Stainless Steel Investment.” The roundtable discussion will
take place from 1:00 – 2:00 p.m. Eastern on Wednesday, June 6th at
booth #375 within the BioProcess Zone’s BPI Theatre. It will
be part of the BPI Theatre’s “Emerging Techniques, Technologies and
Strategies” track.
- Sun Ra Bullins, director of manufacturing at Avid, will make a
presentation titled, “The Perks and Pitfalls of a Single-Use
Biopharmaceutical Facility.” The presentation will take place
from 3:40 – 4:00 p.m. Eastern on Wednesday, June 6th at booth #375
within the BioProcess Zone’s BPI Theatre. It will be part of
the BPI Theatre’s “Emerging Techniques, Technologies and
Strategies” track.
For more information on the BIO International
Convention, please visit: http://convention.bio.org/.
About Avid Bioservices,
Inc.Avid Bioservices is a dedicated contract development
and manufacturing organization (CDMO) focused on development and
cGMP manufacturing of biopharmaceutical products derived from
mammalian cell culture. The company provides a comprehensive
range of process development, high quality cGMP clinical and
commercial manufacturing services for the biotechnology and
biopharmaceutical industries. With 25 years of experience
producing monoclonal antibodies and recombinant proteins in batch,
fed-batch and perfusion modes, Avid's services include cGMP
clinical and commercial product manufacturing, purification, bulk
packaging, stability testing and regulatory strategy, submission
and support. The company also provides a variety of process
development activities, including cell line development and
optimization, cell culture and feed optimization, analytical
methods development and product characterization.
www.avidbio.com
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Okt 2023 bis Okt 2024